Dr. Lynn G. Feun, MD

Dr. Feun practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Feun's NPI, 1902832520, was assigned on June 24, 2006. Dr. Feun graduated from Wayne State University School Of Medicine in 1974. Dr. Feun holds Florida license ME47736.

Dr. Feun's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Feun's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feun practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Feun's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Feun is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Feun's licenses on file in 3 states: Florida, Michigan and Texas.

Dmand AI lists breast cancer and prostate cancer among the conditions Dr. Feun treats.

CMS data shows 385 Medicare services from Dr. Feun across 4 procedure codes in 2024, for 160 Medicare patients. Medicare paid $30,930 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 160 Medicare patients who saw Dr. Feun in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feun's median patient age at 71, with 39% women.

In 2024, Dr. Feun wrote 359 Medicare Part D claims for 71 patients. 85% of them were for generic drugs. CMS names the drug for 221 of them, across 8 drugs with 11 or more claims each, at $3,094 in total drug cost. In 2023, CMS named 296 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Feun for performance year 2024, reported as part of a group. Dr. Feun accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Feun as offering telehealth.

Dmand AI links 161 papers to Dr. Feun, published from 2002 to 2024. 2019 was the busiest year, with 6. The most frequent topics are Brain Neoplasms, Melanoma and Antineoplastic Combined Chemotherapy Protocols. Dr. Feun has published most often in J Neurooncol. Dr. Feun's most frequent co-authors are Niramol Savaraj, MD, Howard J. Landy, FACS, MD and Robert S. Benjamin, MD.

Dmand AI links Dr. Feun to 8 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Liver Neoplasms, Carcinoma, Hepatocellular and Glioblastoma.

CMS Open Payments shows 80 general payments to Dr. Feun from 21 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Merck Sharp & Dohme Corporation paid the most, $565.

Dmand AI lists 2 awards for Dr. Feun, most recently CMS Stage 1 EHR in 2013.

Dr. Feun graduated from Wayne State University School Of Medicine in 1974. Dr. Feun is a member of ASCO.

Dr. Feun is in network with 12 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.